Details

Autor(en) / Beteiligte

• Nagase, Satoshi
• Iyoda, Tomokazu
• Kanno, Hiroshi
• Akase, Tomohide
• Arakawa, Ichiro
• Inoue, Tadao
• Uetsuka, Yoshio

Titel

Comparison of the Cost-Effectiveness of the SOX and COX Regimens in Patients with Unresectable Advanced and Recurrent Colorectal Cancer Using a Clinical Decision Analysis Approach

Ist Teil von

• Gan to kagaku ryoho, 2016-10, Vol.43 (10), p.1201

Ort / Verlag

Japan

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Phase III clinical trials have comfirmed that the S-1 plus oxaliplatin(SOX)is inferior to the capecitabine plus oxaliplatin (COX)regimen in the treatment of metastatic colorectal cancer.On the basis of these findings, we compared, using a clinical decision analysis-based approach, the cost-effectiveness of the SOX and COX regimens.Herein, we simulated the expected effects and costs of the SOX and COX regimens using the markov model.Clinical data were obtained from Hong's 2012 report.The cost data comprised the costs for pharmacist labor, material, inspection, and treatment for adverse event, as well as the total cost of care at the advanced stage.The result showed that the expected cost of the SOX and COX regimen was 1,538,330 yen, and 1,429,596 yen, respectively, with an expected survival rate of 29.18 months, and 28.63 months, respectively.The incremental cost-effectiveness ratio of the SOX regimen was 197,698 yen/month; thus, the SOX regimen was found to be more cost-effective that the COX regimen.